

FINAL PROGRAMME

# 4th Scientific Summit

Tobacco Harm Reduction:  
Novel products, Research & Policy

by **SC**HRE

*Virtual*

29 & 30 SEPTEMBER 2021

[www.nosmokesummit.org](http://www.nosmokesummit.org)

# 4th Scientific Summit

Tobacco Harm Reduction:  
Novel products, Research & Policy

| 29 & 30 SEPTEMBER 2021

## ORGANISERS


### ORGANISED BY

**SOHRE** International  
Association  
on Smoking Control  
& Harm Reduction

### SUPPORTED BY



### SUPPORTING ORGANISATIONS



Κυπριακό Ινστιτούτο Αναπνευστικών Νοσημάτων – Κ.Ι.Α.Ν.Ο.Σ.  
Cyprus Institute of Respiratory Diseases – C.I.R.D.

# 4th Scientific Summit

Tobacco Harm Reduction:  
Novel products, Research & Policy

| 29 & 30 SEPTEMBER 2021

---

## CONTENTS

---

- 02 CONFERENCE ORGANISERS
- 04 WELCOME NOTE
- 05 SCIENTIFIC PROGRAMME
  - September 29, 2021
  - September 30, 2021
- 17 SPEAKERS' LIST

# 4th Scientific Summit

Tobacco Harm Reduction:  
Novel products, Research & Policy

| 29 & 30 SEPTEMBER 2021

## WELCOME NOTE

The **4th Scientific Summit on Tobacco Harm Reduction: Novel products, Research & Policy** is being held virtually on the 29th & 30th September 2021 and is organised by SCOHRE, the newly founded International Association on Smoking Control & Harm Reduction.

SCOHRE, an association of independent experts on Smoking Control & Harm Reduction, scientists from all sectors, (medical doctors, policy experts, behavioural experts, academics, and other professionals), through constructive dialogue, will help to come up with a new broader approach to smoking control policies.

The 4th Scientific Summit - continuing the works of a very successful virtual 3rd Scientific Summit - worked towards attracting top researchers, clinicians, and scientists from diverse fields, from around the world, to contribute to this year's event.

In 2020, the COVID-19 pandemic and the high risk of a second wave contributed to the decision the 3rd Scientific Summit to become virtual, thus enabling the participation of scientists from around the globe. Fifty renowned speakers from 26 countries and 300 attendees from 38 countries worldwide participated online. The 4th Scientific Summit was decided to be held virtually also.

The frequency of alternative tobacco product use (e-cigarettes, Heat-not-Burn products, loose leaf, snus, etc.) among smokers and the association with switch and quit attempts is increasing; the scientific community is debating, in the attempt to explain the benefits and the risks associated with these products.

The **objectives of the Scientific Summit** are to offer opportunities for scientists of different countries to:

- Present, discuss, and challenge recent data related to the topics of Tobacco Harm Reduction and Tobacco Control
- Discuss and debate on scientific, technological, medical, regulatory, legal and policy issues for advancing the technical capacity of the participating countries
- Provide an environment where regulatory authorities and policy makers may present to the scientific and medical communities their prospective course of action.

### CONGRESS SECRETARIAT

MINDVIEW

59, Mousson Str., 11524, Athens, Greece

Tel.: +30 210 6231305

Email: [info@nosmokesummit.org](mailto:info@nosmokesummit.org)

URL: [www.mind-view.gr](http://www.mind-view.gr)

# 4th Scientific Summit


Tobacco Harm Reduction:  
Novel products, Research & Policy

| 29 & 30 SEPTEMBER 2021

---

## FINAL PROGRAMME

---



## FINAL PROGRAMME

### WEDNESDAY, 29 September 2021

#### HALL A

9:30-10:00

#### Opening remarks

#### Goals of the 4th Scientific Summit on Tobacco Harm Reduction

By the Organizing Committee

#### RESEARCH TRACK SESSION I\*

#### Basic Science\*

Chair: *Konstantinos Poulas*

*\*10 min presentations*

10:00-11:30

#### Toxicology and aerosol chemistry [01-04]

AEROSOL FROM A HEATED TOBACCO PRODUCT HAS LESS EFFECT ON LIVER DETOXIFYING ENZYMES THAN CIGARETTE SMOKE [01]

*David Bovard - PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland*

IN VITRO COMPARISON OF CONVENTIONAL CIGARETTE AND NOVEL REDUCED HARM PRODUCTS ON THE DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION [02]

*Georgios Karanasios - University of Patras, Greece*

ABSENCE OF SOLID PARTICLES GENERATED FROM THERMAL PROCESSES IN THE AEROSOL FROM AN ELECTRICALLY HEATED TOBACCO PRODUCT [03]

*Teemu Kärkelä - VTT Technical Research Centre of Finland Ltd, Espoo, Finland*

COMBUSTED CIGARETTES VERSUS HEATED TOBACCO PRODUCTS: COMPARISON FROM THE POINT OF VIEW OF PARTICULATE MATTER EMISSION AND SOLUBLE MATTER [04]

*María Ángeles Lillo-Ródenas - University of Alicante, Spain*

## FINAL PROGRAMME

### **Biomarkers' evaluation in animal or human studies [05]**

IN VITRO EVALUATION OF JUUL DIFFERENT FLAVOR PRODUCTS ON HUMAN ALVEOLAR CELL LINES

**Konstantinos Mesiakaris** - Department of Pharmacy, University of Patras, Greece

### **Preclinical evaluation [06-07]**

ELECTRONIC NICOTINE DELIVERY SYSTEMS EXHIBIT LOWER TOXICITY COMPARED TO CIGARETTES. THE "REPLICA STUDY GROUP" EXPERIENCE [06]

**Massimo Caruso** - Department of Biomedical and Biotechnological Sciences, University of Catania, Italy

TOXICOLOGICAL ASSESSMENT OF THE AEROSOL GENERATED BY A NOVEL PIN-BASED HEATING SYSTEM IN HUMAN BRONCHIAL EPITHELIAL CELLS AND ORGANOTYPIC SMALL AIRWAY EPITHELIAL CULTURES [07]

**Majeed Shoaib** - PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland

11:30-13:00

### **SESSION**

**Tobacco control policy: prevention, harm reduction, cessation**

Chairs: **Karl Erik Lund & Anastasia Barbouni**

Speakers:

■ The Global Burden of Smoking: what have we achieved so far?

**Konstantinos Kesanopoulos**

■ Tobacco Harm Reduction myths and facts. What is the evidence?

**Giuseppe Biondi Zoccai**

Panel Discussion: **Ignatios Ikonmidis, Effie Polyzogopoulou**

## FINAL PROGRAMME

### 13:00-14:30 **RESEARCH TRACK SESSION II**

Chair: **Evis Bagdates**

#### **Epidemiology & Social Issues [08-10]**

INTERNET-BASED SURVEILLANCE SYSTEMS ON SMOKING AND ALTERNATIVE TOBACCO PRODUCT USE: EXPLORING THE POTENTIAL OF TWITTER [08]

**Christos Markou** - *Special Academic Unit for the Study of Smoking Behavior, Laboratory of Hygiene and Epidemiology, Department of Public and Community Health, School of Public Health University of West Attica, Athens, Greece*

CURRENT TOBACCO CONTROL POLICIES AND OBSERVATION OF E-CIGARETTE USE AND SMOKING CESSATION AMONG RESIDENTS AT A SUBSTANCE ADDICTION REHABILITATION FACILITY IN MALAYSIA [09]

**Prem-Kumar Shanmugam** - *PhD Psychology, CEO & Clinical Director, Solace Asia Sdn. Bhd., Selangor, Malaysia*

A JAPANESE PHARMACY STUDY IN CESSATION PATIENTS TO EXPLORE THE COLLECTION OF TOBACCO USE DATA TO SUPPLEMENT REAL WORLD EVIDENCE [10]

**Angela van der Plas** - *PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland*

#### **Regulatory Issues [11-12]**

TOWARDS A SMOKE-FREE FUTURE [11]

**Peter Harper** - *Dr, Consultant Medical Oncologist LOC, London, UK, Harm Reduction Consultant to PMI*

SARS-COV-2, SMOKING, AND NICOTINE CONSUMPTION: INVESTIGATING THE INTENDED AND UNINTENDED CONSEQUENCES OF RESPONSES TO COVID-19 AROUND THE WORLD [12]

**Samuel Hampsher-Monk** - *BOTEC Analysis*

## FINAL PROGRAMME

### Smoking Cessation [13-15]

HABITA PROJECT, TO STUDY THE SMOKING HABIT AMONG PATIENTS AND FACE THEIR WITHDRAWAL [13]

**Vivencio Barrios** - Ramón y Cajal Hospital, Madrid, Spain

E-CIGARETTES AND SMOKING: CORRELATION, CAUSATION, AND SELECTION BIAS [14]

**James Prieger** - Pepperdine University, California, USA

A MULTI-DISCIPLINARY INVESTIGATION INTO THE DRIVERS OF SMOKING CESSATION IN FIVE COUNTRIES WITH ANDS MARKETS [15]

**Samuel Hampsher** - BOTECH Analysis

14:30-16:00

### PANEL DISCUSSION

**The Future of smoking in Europe – Regulation | Data Generation & Cancer Plan**

Chair: **Ignatios Ikonomidis**

Speakers:

- Sweden: Harm Reduction and Endgame Target Achieved, **Karl Fagerstrom**
- SCOHRE position on “Beat Cancer” Plan, **Ignatios Ikonomidis**

Panelists:

**Fernando Fernández Bueno**

**Ioannis Boukovinas**

**Bengt Wiberg**

16:00-17:00

### EXPERTS PANEL

**Latin American experts share their experience on Tobacco Harm Reduction and relevant ethics and people’s rights issues**

Chair: **Monica Gorgulho**

## FINAL PROGRAMME

Panelists:

**Zara Snapp** (Mexico)

**Maria Alejandra Medina** (Colombia)

**Enrique Teran** (Ecuador)

**Alexandro Lucian** (Brazil)

*In collaboration with DIRETA & ATS*

17:00-18:30

### RESEARCH TRACK SESSION III

#### Clinical Assessment of THR & novel products (1) [16-20]

Chairs: **Michael G. Toumbis & Panos E. Vardas**

#### LECTURE

##### New Nicotine Oral Pouches, **Karl Fagerstrom**

FAVOURABLE CHANGES IN BIOMARKERS OF POTENTIAL HARM WHEN SWITCHING FROM CIGARETTE SMOKING TO USING A TOBACCO HEATING PRODUCT FOR 6 MONTHS [16]


**Nathan Gale** - British American Tobacco (Investments) Limited, Research and Development, Southampton, UK

EVALUATING RESPIRATORY SYMPTOMS IN SMOKERS WHO SWITCHED TO ENDS [17]

**Stacey McCaffrey** - JUUL Labs Inc

RESPIRATORY AND CARDIOVASCULAR HEALTH EFFECTS OF E-CIGARETTE SUBSTITUTION FOR CIGARETTE SMOKING: A LIVING SYSTEMATIC REVIEW [18]

**Maria-Ahmed Qureshi** - Fellowship Researcher, Department of Clinical and Experimental Medicine, University of Catania, Italy



## FINAL PROGRAMME

---

USE OF INTERRUPTED TIME SERIES ANALYSIS FOR EVALUATING HOSPITALIZATION RATES BEFORE AND AFTER THE INTRODUCTION OF HEATED TOBACCO PRODUCTS IN THE JAPANESE MARKET [19]

**Angela van der Plas** - PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland

SMOKING BEHAVIOR OF TOBACCO CIGARETTE SMOKERS AFTER SWITCHING TO ELECTRONIC CIGARETTE OR HEATED TOBACCO PRODUCTS DURING 3 YEARS OF FOLLOW-UP [20]

**Gavriella Kostelli** - 2nd Cardiology Department, Attikon Hospital, National and Kapodistrian University of Athens, Greece

18:30-19:00

### KEYNOTE LECTURE

**Balancing considerations of the risks & benefits of e-cigarettes,**  
**Kenneth E. Warner**

Chair: **Karl Erik Lund**

### HALL B

---

13:00-14:30

### RESEARCH TRACK SESSION IV

**Clinical Assessment of THR & novel products (2) [21-25]**

Chair: **Konstantinos Katogiannis**

FEATURES OF THE EFFECTIVENESS OF COMBINED ANTIHYPERTENSIVE THERAPY IN MEN, DEPENDING ON THE TYPE OF TOBACCO PRODUCTS USED [21]

**Fedor Kovalenko** - Krasnodar outpatient clinic, Southern District Medical Center, Federal Medical and Biological Agency, Russia

## FINAL PROGRAMME

---

NICOTINE PHARMACOKINETICS OF MODERN ORAL NICOTINE POUCHES [22]

**Michael McEwan** - British American Tobacco (Investments) Limited, Research and Development, Southampton, UK

B-CARBOLINES AS REVERSIBLE MONOAMINE OXIDASE INHIBITORS [23]

**Alja Prah** - Theory Department, National Institute of Chemistry, Ljubljana, Slovenia & Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

RESPIRATORY FUNCTION, PHYSICAL CAPACITY, AND METABOLIC SYNDROME COMPONENTS IN COMBUSTIBLE CIGARETTES AND HEATED TOBACCO PRODUCTS USERS: A TWO-YEAR FOLLOW-UP COHORT STUDY [24]

**Almaz Sharman** - MD, PhD, Academy of Preventive Medicine of Kazakhstan, Almaty, Republic of Kazakhstan

THE MIDTERM DIFFERENTIAL EFFECTS OF HEAT-NOT-BURN AND CONVENTIONAL CIGARETTES ON CORONARY FLOW, VASCULAR FUNCTION AND OXIDATIVE STRESS ARE INDEPENDENT OF NICOTINE LEVELS [25]

**Margarita Marinou** - Onassis Cardiac Surgery Center, Athens, Greece

## FINAL PROGRAMME

---

### THURSDAY, 30 September 2021

#### HALL A

---

- 10:00-11:00 **PANEL DISCUSSION**  
**To what extent scientific data drive political decisions?**  
Chair: *Dimitri Richter*
- Panelists:  
*Eva Kaili*  
*Emil Toldy-Schedel*  
*Manuel Pais Clemente*
- 11:00-11:30 **LECTURE**  
**Why the UK has taken a compassionate approach to vaping,**  
*Caitlin Notley*  
Chair: *Giuseppe Biondi Zoccai*
- 11:30-12:30 **PANEL DISCUSSION**  
**Independent Verification of industry data for novel products & interventions**  
Chair: *Demetrios Kouretas*
- Panelists:  
*Konstantinos Farsalinos*  
*Giovanni Li Volti*  
*Massimo Caruso*
- 12:30-13:00 **SESSION**  
**Smoking in the context of COVID-19 pandemic**  
Chair: *Ioannis Lekakis*

## FINAL PROGRAMME

Speakers:

- Tobacco use and the risk of COVID-19, **Konstantinos Farsalinos**
- Tobacco use and severity of COVID-19, **Michael G. Toumbis**

13:00-14:00

### EXPERTS PANEL

**African experts share their experience on Tobacco Harm Reduction**

Chairs: **Fares Mili & Solomon Rataemane**

Speakers:

- Advocacy and policies in Africa: What's wrong and what would be the solution? **Kgosi Letlape** (South Africa)
- What's wrong in tobacco policy approach and what would be the solution? The point of view of consumers in Africa, **Joseph Magero** (Kenya)
- Specificities of tobacco addicts with psychiatric comorbidities: the need of nicotine. The Moroccan experience, **Imane Kendili** (Morocco)
- The specificities of tobacco users and other substance users: The need for a harm reduction unified approach, **Uta Ouali** (Tunisia)

14:00-15:00

### PANEL DISCUSSION

**Transformation of the tobacco industry: strategy, competition, and ethics**

Chair: **Clive Bates**

Panelists:

- Gizelle Baker** (PMI)
- Sharon Goodall** (BAT)
- Ian Jones** (JTI)
- Joe Murillo** (JUUL)

15:00-16:00

### SESSION

**Economic dimensions of Smoking Control and Harm Reduction**

Chair: **Andrzej M. Fal**

## FINAL PROGRAMME

Speakers:

*Andrzej M. Fal*

*Tomas Drucker*

Panelists:

*Victor Mravčík*

*Arkadi Sharkov*

*Emanuele Bracco*

16:00-16:30

### LECTURE

**Is Differential Taxation a means to promote Public Health Strategies?**

*Michael Pesko*

Chair: *Athanassios Vozikis*

16:30-17:30

### PANEL DISCUSSION

**Ethics & people's rights**

Chair: *David T. Sweanor J.D.*

Panelists:

*Stanimir Hasardzhiev*

*Charles A. Gardner*

*Lynn T. Kozlowski*

17:30-18:00

### KEYNOTE LECTURE

**Two different approaches towards THR - Contrasting the cases of New Zealand & Australia, *Joe Kosterich***

Chair: *Anastasia Barbouni*


18:30-19:00

### SCOHRE Presentation

**Mission, Principles & Membership**

### CLOSING REMARKS

**Q&A**



## FINAL PROGRAMME

---

### HALL B

---

13:00-14:30

#### EXPERTS PANEL

**Asian experts share their experience on Tobacco Harm Reduction**

Chair: *Sharifa Ezat Wan Puteh*

Panelists:

*Amaliya Amaliya (Indonesia)*

*Asrul Akmal Shafie (Malaysia)*

*Hiroya Kumamaru (Japan)*

*Rajesh N. Sharan (India)*

*Lorenzo Mata (Philippines)*

#### Programme Timezone

The Programme features Athens, Greece time (GMT+3 hrs)

#### Other popular timezones:

Brussels, Belgium (GMT+2)

Sao Paulo, Brazil (GMT-3)

Houston, TX, USA (GMT-6)

Singapore / Beijing (GMT+8)



# 4th Scientific Summit

Tobacco Harm Reduction:  
Novel products, Research & Policy

| 29 & 30 SEPTEMBER 2021

---

## **SPEAKERS' LIST**

---

## SPEAKERS' LIST

<b>Amaliya Amaliya</b>	M.Sc., PhD, Dentist, Department of Periodontology, Faculty of Dentistry, Universitas Padjadjaran, Bandung, Indonesia
<b>Evis Bagdades</b>	Clinical Associate Professor of Respiratory Medicine, University of Nicosia Medical School, Nicosia, Cyprus
<b>Gizelle Baker</b>	PhD, Vice President Global Scientific Engagement, Philip Morris International
<b>Anastasia Barbouni</b>	MD, MSc, PhD, Professor of Public Health and Disease prevention, Department of Public and Community Health, School of Public Health, University of West Attica, Athens, Greece
<b>Clive Bates</b>	Director, Counterfactual Consulting Limited, London, United Kingdom
<b>Giuseppe Biondi Zoccai</b>	Associate Professor in Cardiology, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Italy
<b>Ioannis Boukovinas</b>	MD, PhD, PharmaD, Medical Oncologist, Scientific Director, Oncology Unit, Bioclinic of Thessaloniki, Greece
<b>Emanuele Bracco</b>	Associate Professor in Economics, University of Verona, Italy
<b>Massimo Caruso</b>	PhD in Respiratory Diseases, Assistant Professor in Biochemistry and Researcher, Center of Excellence for the acceleration of HArm Reduction (CoEHAR), University of Catania, Italy
<b>Tomas Drucker</b>	JUDr. Ing, former Minister of Health, Minister of Interior of the Slovak Republic
<b>Sharifa Ezat Wan Puteh</b>	Professor of Hospital Management and Health Economics; Deputy Dean (Relation & Wealth Creation), Faculty of Medicine, UKM Medical Centre; Previous Head of International Centre for Casemix and Clinical Coding (ITCC), UKM Medical Centre, Kuala Lumpur, Malaysia
<b>Karl Fagerstrom</b>	Professor Emeritus; President, Fagerstrom Consulting, Sweden
<b>Andrzej M. Fal</b>	Prof. h.c., MD, PhD, MBA, FAAAAI, President, Polish Society of Public Health; Head, Department of Allergy, Lung Diseases and Internal Medicine, Central Clinical Hospital, Ministry of Interior; Director, Institute of Medical Science, UKSW, Warsaw, Poland
<b>Konstantinos Farsalinos</b>	MD, MPH, Adjunct Professor, King Abdulaziz University, Saudi Arabia; Senior Researcher, University of Patras; School of Public Health, University of West Attica; Data & Media Lab, University of Peloponnese, Greece
<b>Fernando Fernández Bueno</b>	MD, MSc, Oncological Surgery Hospital Gomez Ulla - Madrid; President of the Platform of Tobacco Harm Reduction, Madrid, Spain

## SPEAKERS' LIST

<b>Charles A. Gardner</b>	PhD, Executive Director, International Network of Nicotine Consumer Organizations (INNCO), New York, USA
<b>Sharon Goodall</b>	Group Head of MRTP Science, British American Tobacco (BAT)
<b>Monica Gorgulho</b>	Psychologist specialized in addiction, International Harm Reduction Association (IHRA), Specialist in Abuse Drugs by the UN (United Nations - Narcotics Division), Sao Paulo, Brazil
<b>Stanimir Hasardzhiev</b>	Chairman, National Patients Organization, Bulgaria
<b>Ignatios Ikonomidis</b>	MD, PhD, FESC, FAHA, Professor of Cardiology, Director of Echocardiography and the Laboratory of Preventive Cardiology, 2nd Cardiology Department, National and Kapodistrian University of Athens, Greece
<b>Ian Jones</b>	PhD, R&D Principal Scientist at Japan Tobacco International (JTI), Geneva, Switzerland
<b>Eva Kaili</b>	Member of the European Parliament, Group of the Progressive Alliance of Socialists and Democrats
<b>Konstantinos Katogiannis</b>	Academic fellow, 2nd Cardiology Department of National and Kapodistrian University of Athens, Greece
<b>Imane Kendili</b>	Psychiatrist and Author, Head of the Addictology and Associated Pathologies Unit at Clinique Andalouss, Morocco
<b>Konstantinos Kesanopoulos</b>	Biologist, MSc, PhD, Special Academic Unit for the Study of Smoking Behavior, Laboratory of Hygiene & Epidemiology, Department of Public & Community Health, School of Public Health, University of West Attica, Athens, Greece
<b>Joe Kosterich</b>	M.B.B.S (WA) 1985; Chairman, Australian Tobacco Harm Reduction Association, Woodvale, Australia
<b>Demetrios Kouretas</b>	Professor, Animal Physiology - Toxicology, University of Thessaly, Larissa, Greece; President of the Hellenic Society of Toxicology, Larissa, Greece
<b>Lynn T. Kozlowski</b>	PhD, Professor of Community Health and Health Behavior; Former dean of the School of Public Health and Health Professions, University at Buffalo, New York, USA
<b>Hiroya Kumamaru</b>	MD, PhD, Cardiovascular surgeon, Vice Director of AOI International Hospital, Kawasaki, Japan
<b>Ioannis Lekakis</b>	Professor of Cardiology, Director 2nd Cardiology Department, Attikon Hospital, Athens, Greece

## SPEAKERS' LIST

<b>Kgosi Letlape</b>	Dr, President of the HPCSA, Health Professions Council of South Africa; Chairperson, Medical and Dental Board, Johannesburg, South Africa
<b>Giovanni Li Volti</b>	Full professor of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, Italy
<b>Alexandro Lucian</b>	President, DIRETA, Brazil
<b>Karl Erik Lund</b>	Ph.D, Research Director of the Department of Alcohol, Drug and Tobacco Research, Norwegian Institute for Public Health, Oslo, Norway
<b>Joseph Magero</b>	Chairman, Campaign for Safer Alternatives (CASA); Treasurer, International Network of Nicotine Consumer Organisations (INNCO), Kenya
<b>Lorenzo Mata</b>	President, Quit for Good, Philippines
<b>Maria Alejandra Medina</b>	Technical Coordinator, Plataforma Nicotina Reducción de Riesgos y Daños, Corporación Acción Técnica Social (ATS), Colombia
<b>Fares Mili</b>	MD, Pulmonologist, Allergist, Specialist in addiction behaviors, President of the NGO «Société Tunisienne de Tabacologie et des comportements d'addiction - STTACA», Tunis, Tunisia
<b>Viktor Mravčík</b>	Associate Professor, MD, PhD, Head of the National Monitoring Centre for Drugs and Addiction, Czech Republic
<b>Joe Murillo</b>	Chief Regulatory Officer, JUUL Labs, USA
<b>Caitlin Notley</b>	Professor of Addiction Sciences, University of East Anglia, UK
<b>Uta Ouali</b>	Senior psychiatrist, Razi Hospital; Lecturer, University of Tunis El Manar Medical School, Tunisia
<b>Manuel Pais Clemente</b>	MD, PhD, Retired Full Professor Department of Otorhinolaryngology, Porto University School of Medicine; Vice-President European Medical Association; President World Voice Consortium, Porto, Portugal
<b>Michael Pesko</b>	Health Economist, Associate Professor, Department of Economics, Georgia State University, Atlanta, Georgia, USA
<b>Eftihia (Effe) Polyzogopoulou</b>	MD, PhD, Assistant Professor of Emergency Medicine, National and Kapodistrian University of Athens, Greece
<b>Konstantinos Poulas</b>	PhD, Associate Professor of Biochemistry, Laboratory of Molecular Biology and Immunology, Department of Pharmacy, University of Patras, Greece

## SPEAKERS' LIST

<b>Solomon Tshimong Rataemane</b>	MD, Professor, Secretary General WAPR 2014-2020, Dr George Mukhari Academic Hospital, HOD Psychiatry UFS 1998-2003, (HOD) 2003-2019; Dept of Psychiatry, Sefako Makgatho Health Sciences University 2003-2019; Chair, Ministerial Advisory Committee on Mental Health, South Africa
<b>Dimitri Richter</b>	MD, FESC, FAHA, Head of Cardiology Department, Euroclinic Hospital, Athens, Greece
<b>Asrul Akmal Shafie</b>	Professor of Pharmacoeconomics, BPharm (Hons) (USM), Pg Dip Health Econ (Trefforest), PhD (Cardiff); School of Pharmaceutical Sciences, Universiti Sains Malaysia
<b>Rajesh N. Sharan</b>	Professor, Radiation and Molecular Biology Unit, Department of Biochemistry, North-Eastern Hill University, Shillong, India
<b>Arkadi Sharkov</b>	Healthcare consultant, Bulgaria
<b>Zara Snapp</b>	Co-Founder, Instituto RIA, Mexico
<b>David T. Sweanor J.D.</b>	Chair of the Advisory Board, Centre for Health Law, Policy & Ethics, University of Ottawa, Canada
<b>Enrique Teran</b>	MD, PhD, Professor, School of Medicine, Universidad San Francisco de Quito, Ecuador
<b>Emil Toldy-Schedel</b>	Medical Doctor, General Director of the St. Francis Hospital, Budapest, Hungary
<b>Michael G. Toumbis</b>	MD, PhD, FCCP, Pneumonologist, President of the Cyprus Institute of Respiratory Diseases, Cyprus
<b>Panos E. Vardas</b>	Professor, MD, PhD (London, UK); Chairman of Heart Sector, Hygeia Hospitals Group; Past President of the European Society of Cardiology; Visiting Professor, Imperial College, UK; Chief Strategy Officer of ESC/ European Heart Agency, Brussels, Athens, Greece
<b>Athanassios Vozikis</b>	Associate Professor, Director of The Laboratory of Health Economics and Management of University of Piraeus, Greece
<b>Kenneth E. Warner</b>	Avedis Donabedian Distinguished University Professor Emeritus of Public Health; Dean Emeritus, University of Michigan School of Public Health, Ann Arbor, Michigan, USA
<b>Bengt Wiberg</b>	CEO, Sting Free AB; Founder, EUforSnus, Sweden

*Research Track Sessions Information*

*Presenting authors' details and affiliations are included in the 4th Scientific Summit's Abstract Book.*

